



🛈 🔒 https://apps.na	aaccr.org/ssdi/list/				~	E 🛛 🚖		
c a 📄 2018 Solid Tumo	a 📦 2018 Solid Tumor Rules 🤀 Schemas EOD Data S 🔀 Schemas SSDI Data 🌒 Summary Stage 2018 🐌 Search - SEER Inquiry							
		tion of Central Cancer Registries						
	Home							
		SITE SPECIFIC DATA I	TEMS (S	SDI)/ GRADE				
			(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				
	Home / Schema List							
					Data Last Updated: Feb. 14, 20	19 (Version 1.5)		
	CANCER SCHEMA	LIST						
				? RESOURCES				
	Standard Search O Site/Hist Search	Displaying 118	Schemas	» SSDI Manual				
	Search Term(s)	SEARCH		 » SSDI Manual Appendix » SSDI Manual Appendix 				
				 » Grade Manual 				
				» Change Log				
				Comments or suggestions	concerning the SSDI's are welcome			
					American College of Surgeons			
				CAnswer Forum.				
	Adnexa Uterine Other	Eye Other	Melanoma	Choroid and Ciliary Body	Plasma Cell Disorders			
	Adrenal Gland	Fallopian Tube		Conjunctiva	Plasma Cell Myeloma			
	Ampulla of Vater	Floor of Mouth	Melanoma	Head and Neck	Pleural Mesothelioma			

D Data SEER*RSA 🗙	+			
C û	① A https://staging.seer.cancer.gov/eod_public/list/1.7/			
Setting Started 📄 SEER Hematopo	ioietic a 📄 2018 Solid Tumor Rules 🌓 Summary Stage 2018 🌒 Si	arch - SEER Inquiry 💮 Schemas EOD Data S 🌐	Schemas SSDI Data	
	NH NATIONAL CANCER SEER Registrar	INSTITUTE Staging Assistant		Database Version: EOD_PUBLIC v1.7
	EOD Data V1.7 SEER*RSA		SCHEMA LIST MANUALS STAGI	NG CALCULATOR SOFTWARE CONTACT
	EOD Home ≥ Schema List			
	Cancer Schema List			
	Standard Search O Site/Hi	st Search		Displaying 118 Schemas
	Search Term(s)	Search	>	
	Adnexa Uterine Other	Eye Other	Melanoma Choroid and Ciliary	Plasma Cell Disorders
	Adrenal Gland	Fallopian Tube	Body	Plasma Cell Myeloma
	Ampulla of Vater	Floor of Mouth	Melanoma Conjunctiva	Pleural Mesothelioma
	Anus	Gallbladder	Melanoma Head and Neck	Primary Cutaneous Lymphoma
	Appendix	Genital Female Other	Melanoma Iris	(excluding MF and SS)
	Bile Duct Distal	Genital Male Other	Melanoma Skin	Primary Peritoneal Carcinoma
	Bile Ducts Intrahepatic	GIST	Merkel Cell Skin	Prostate
	Bile Ducts Perihilar	Gum	Middle Ear	Respiratory Other
	Biliary Other	Heart, Mediastinum and Pleura	Mouth Other	Retinoblastoma
	Bladder	HemeRetic	Mycosis Fungoides	Retroperitoneum
	Bone Appendicular Skeleton	Hypopharynx	Nasal Cavity and Ethmoid Sinus	Sinus Other
	Bone Pelvis	III-Defined Other	Nasopharynx	Skin Eyelid
	Bone Spine	Intracranial Gland	NET Adrenal Gland	Skin Other
	Brain	Kaposi Sarcoma	NET Ampulla of Vater	Small Intestine
	Breast	Kidney Parenchyma	NET Appendix	Soft Tissue Abdomen and Thoracic


Name	Default Value	Used for Staging	NAACCR Item	Required By	Metadata
Year of Diagnosis	<blank></blank>	No	NAACCR #390		None
Primary Site	<blank></blank>	Yes	NAACCR #400		None
Histology	<blank></blank>	Yes	NAACCR #522		None
Behavior	<blank></blank>	Yes	NAACCR #523		None
Tumor Size Clinical	<blank></blank>	No	NAACCR #752		None
Tumor Size Pathological	<blank></blank>	No	NAACCR #754		None
Tumor Size Summary	999	Yes	NAACCR #756		None
Regional Nodes Positive	99	No	NAACCR #820		None
Regional Nodes Examined	99	No	NAACCR #830		None
LVI	9	No	NAACCR #1182		None
RX Summ Surgery/Radiation Sequence	<blank></blank>	No	NAACCR #1380		None
RX Summ Systemic/Surgery Sequence	<blank></blank>	No	NAACCR #1639		None
EOD Primary Tumor	999	Yes	NAACCR #772		None
EOD Regional Nodes	999	Yes	NAACCR #774		None
EOD Mets	00	Yes	NAACCR #776		None
SS2018	<blank></blank>	No	NAACCR #764		None
Grade Clinical	9	Yes	NAACCR #3843	All	SSDI
Grade Pathological	9	Yes	NAACCR #3844	All	SSDI
Grade Post Therapy	<blank></blank>	No	NAACCR #3845	CCCR/Canada COC NPCR	SSDI
Lymph Nodes Positive Avillany Level L.I.	~ 9		NAACCR #3882	SEER	SSDI










14		NAACCR
ED/DD Dangaa	Code	Description
ER/PR Ranges	000	ER negative, or stated as less than 1%
If the range on the report uses steps	001-100	1-100 percent
	R10	Stated as 1-10%
smaller than 10 and the range is fully or at	R20	Stated as 11-20%
least 80% contained within a range	R30	Stated as 21-30%
provided in the table, code to that range in	R40	Stated as 31-40%
the table.	R50	Stated as 41-50%
 Report says 1-5%. 	R60	Stated as 51-60%
 Code R10 (1-10%) 	R70	Stated as 61-70%
 Report says 90-95%. 	R80	Stated as 71-80%
Code R99 (91-100% because almost all of the	R90	Stated as 81-90%
range is contained within code R99)	R99	Stated as 91-100%
http://cancerbulletin.facs.org/forums/forum/site-specific-data-items-grade-	2018/8627	77-er-pr-percent-positive











Allre	ed Score	Components		NAACC
Proportio Score		Intensity	Intensity Score	
0	0	None	0	
1	<1	Weak	1	
2	1-10	Intermediate/Moderate	2	
3	11-33	Strong	3	
4	34-66			
5	≥67			
 Registrars ma If either F 	y calculate Allred score roportion score or Inter	re + Intensity score = AI if Proportion score and Intensity score usity score are missing, then registrar ca go with the higher value.	are available) .


- Weak, Intermediate, Moderate, Strong, may be used to assign the score.
 See page 174 of the SSDI manual for additional instructions.


20			NAACCR
	Estro	gen Receptor Total Allred Score	
	Code	Definition	
	00	Total ER Allred score of 0	
	01	Total ER Allred score of 1	
	02	Total ER Allred score of 2	
	03	Total ER Allred score of 3	
	04	Total ER Allred score of 4	
	05	Total ER Allred score of 5	
	06	Total ER Allred score of 6	
	07	Total ER Allred score of 7	
	08	Total ER Allred score of 8	
	X9	Not documented in medical record ER (Estrogen Receptor) Total Allred Score not assessed, or unknown if assessed	







	••• 📎	NAACCR
Pop Quiz		
A patient presents with two tumors in	Data Item	Value
A patient presents with two tumors in the same breast. Multiple specimens from the larger tumor were sent for	ER Summary	1
testing	ER Percent Positive	100
 Specimen 1- Core biopsy 	ER Allred Score	08
• ER POS (100%, 3+)	PR Summary	1
• PR NEG (<1% 2+)	PR Percent Positive	080
 HER2 POS BY IHC (3+) Specimen 2-Core biopsy 	PR Allred Score	08
• ER POS (97%, 3+)	HER 2 IHC	3
∘ PR POS (80%, 3+́) 🔶	HER 2 ISH	9
• HER2 NEG (2+) BY IHC	HER 2 ISH Single Probe	XX.9
 Specimen 3-Lumpectomy ○ ER POS (75%, 1+) ← 	HER 2 ISH Dual Probe	XX.9
• PR NEG (<1% 1+)	HER 2 ISH Dual Probe Ratio	XX.9
• HER2 POS BY IHC (3+)		

















30		NAACCR
Grade and Tumor S	Size	
 Ultrasound: Hypoechoic mass @ 3:00 axis, retroareolar, measures 2.1 cm 	Data Item	Value
 Lumpectomy: 15 mm unifocal invasive 	Primary Site	C50.3
duct [*] carcinóma	Histology/Behavior	8500/3
Grade	Tumor Size Clinical	021
 Biopsy: Invasive ductal carcinoma, well differentiated. 	Tumor Size Pathological	015
 Nottingham grade= 5/9. G1. 	Tumor Size Summary	015
 DCIS, cribriform & micropapillary, low nuclear grade. 	Grade Clinical	1
 Lumpectomy Tubular differentiation: 2 	Grade Pathological	1
 Nuclear pleomorphism: 2 	Grade Post Therapy	
 Mitotic count: 1 Tumor grade: 5/9. Overall grade: 1. 		


31		NAACCR
	Data Item	Value
AJCC Stage	Clinical T	cT2
	Clinical T Suffix	
Clinical Pathological	Clinical N	cN0
• Tumor Size: 2.1 • Tumor Size: 1.	5 Clinical N Suffix	
 Unifocal unifocal Danian al Na da a 	Clinical M	cM0
 Regional Nodes: Regional Node 00/03 SN 	S: Clinical Stage Group	1B
 Distant Mets: Neg Distant Mets: Neg 	lea	
 Grade: G1 Grade: G1 	Pathological T	pT1c
 Her2: Neg Her2: Neg 	Pathological T Suffix	
• ER: Pos • ER: Pos	Pathological N	pN0
• PR: Pos • PR: Pos	Pathological N Suffix	(sn)
	Pathological M	cM0
	Pathological Stage Group	1A
		2060


32				NAACC
	Summary Stage/E	EO	D	
SS2018	3 Description	100	Any size tumor	
0	In situ, intraepithelial, noninvasive		Confined to breast tissue and fat including nipple and/or areola Localized, NOS	
	 In situ: noninfiltrating; intraepithelial 		EXCLUDES: skin invasion of breast, nipple and areola (see code 200)	
	Intraductal WITHOUT infiltration Lobular neoplasia, grade 3 (LIN 3) Paget disease, in situ	200	Any size tumor Attachment or fixation to pectoral muscle(s) or underlying tumor	
1	Localized only (localized, NOS)	Code	Description	
	 Confined to breast tissue and fat including nipple and/or areola Paget disease WITH or WITHOUT underlying tumor 	000	No clinical regional lymph node involvement	
2	Regional by direct extension only	030	PATHOLOGICAL assessment only	
	 Attachment or fixation to pectoral muscle(s) or underlying tumor Chest wall 		ITCs only (malignant cell clusters no larger than 0.2 mm) in regional lymph node(s)	
	 Criest Wall Deep fixation Extensive skin involvement WITH or WITHOUT dermal lymphatic filtration 	050	PATHOLOGICAL assessment only	
	> Edema of skin		Positive molecular findings by reverse transcriptase polymerase chain reaction (RT-PCR), no I	ITCs detected
	En cuirasse Erythema Inflammation of skin	070	No regional lymph node involvement pathologically (lymph nodes removed and pathologically negative) WITHOUT ITCs or ITC testing unknown	
			Micromotostasis loss than or oqual to 2 mm	


















		NAAC
SSDI's	Data Item	Value
Tumor Markers	ER Summary	1
	ER Percent Positive	094
Markers from biopsy specimen	ER Allred Score	08
 ER= 94%, strong (3+) PR= 99%, strong (3+) 	PR Summary	1
• Ki-67= 3-5%	PR Percent Positive	099
HER2 IHC not performed.	PR Allred Score	08
HER2 ISH= Not amplified.	HER 2 Overall Summary	0
Average HER2 copy number: 2.28	HER 2 IHC Summary	9
Average CEP17 copy number: 2.00	HER 2 ISH Summary	0
Ratio of average HER2/CEP17: 1.1	HER 2 Single Probe Copy Number	XX.9
Ũ	HER 2 Dual Probe Copy Number	2.2
Sample adequate for analysis: Yes	Her 2 ISH Dual Probe Ratio	1.1
Ki-67= 3-5%.	Ki-67	3.1


40			NAACCR				
Other SSDI's	Other SSDI's						
Record did not indicate an	Data Item	Value					
Oncotype DX or other	Oncotype DX Recur Score	XX9					
multigene signature test was	Oncotype Dx Risk Level Invasive	9					
 Performed. ○ Patient was eligible for Oncotype DX 	Oncotype DX Recur Score - DCIS	XX6					
	Oncotype Dx Risk Level - DCIS	6					
 Stage 1 or 2a ER/PR positive 	Multigene Signature Method	9					
 Her2 negative 	Multigene Signature Result	9					
Patient did not have	Response Neoadjuvant Therapy	0					
neoadjuvant treatment							

















47				NAACCR
	Grade and ⁻	Tumor	Si	70
	Data Item	Value	Code	Description
	Primary Site	C50.9	1	G1: Low combined histologic grade (favorable), SBR score of 3-5 points
	Histology/Behavior	8500/3	2	G2: Intermediate combined histologic grade (moderately favorable); SBR score of 6-7 points
	Tumor Size Clinical	026	3	G3: High combined histologic grade (unfavorable); SBR score of 8-9 points
	Tumor Size Pathological	017	L	Nuclear Grade I (Low) (in situ only)
	Tumor Size Summary	017	М	Nuclear Grade II (interMediate) (in situ only)
	Grade Clinical	2	Н	Nuclear Grade III (High) (in situ only)
	Grade Pathological	3	A	Well differentiated
	Grade Post Therapy		В	Moderately differentiated
	.,		С	Poorly differentiated
			D	Undifferentiated, anaplastic
			9	Grade cannot be assessed (GX); Unknown
			K	


48			NAACCR
	Data Item	Value	
AJCC Stage	Clinical T	cT2	
	Clinical T Suffix	(m)	
Clinical Pathological	Clinical N	cN0	
• Tumor Size: 2.6 • Tumor Size: 1.5	Clinical N Suffix		
 Multifocal Multifocal Regional Nodes: Regional Nodes: 	Clinical M	cM0	
Neg 02/04 SN	Clinical Stage Group	1B	
Distant Mets: Neg Distant Mets: Neg			
• Grade: G2 • Grade: G3	Pathological T	pT1c	
∘ Her2: Neg ∘ Her2: Neg	Pathological T Suffix	(m)	
• ER: Pos • ER: Pos	Pathological N	pN1a	
• PR: Pos • PR: Pos	Pathological N Suffix	(sn)	
	Pathological M	cM0	
	Pathological Stage Group	1B	



50			NAACCR		
Summary Stage/EOD/Nodes					
Four lymph no	Four lymph nodes removed during sentinel node procedure.	Data Item	Value		
0		Summary Stage 2018	3 Regional Nodes		
·		EOD Primary Tumor	100		
Two were posit	Two were positive for metastasis.	EOD Lymph Regional Nodes	200		
metastasis.		EOD Mets	00		
No further lymr	No further lymph nodes removed.	Regional Nodes Positive	02		
5 1		Regional Nodes Examined	04		
Terrioved.		Sentinel Nodes Positive	02		
		Sentinel Nodes Examined	04		







		NAACCR				
SSDI's	Data Item	Value				
Tumor Markers	ER Summary	1				
	ER Percent Positive	091				
Biopsy Specimen 5+3=8	ER Allred Score	08				
• ER (One higher) > 90%, 3+	PR Summary	1				
• PR (⁽⁹¹⁾) 25%, 2-3+	PR Percent Positive	045				
• Her 2 IHC 0 3+3=6	PR Allred Score	07				
(Lowest	HER 2 Overall Summary	0				
Tumor Specimen 5+3=8 rumber in range (71)	HER 2 IHC Summary	1				
• ER 71-99%, 3+	HER 2 ISH Summary	9				
• PR 45%, 3+ 4+3=7	HER 2 Single Probe Copy Number	XX.9				
∘ Her 2 IHC 1+, Negative	HER 2 Dual Probe Copy Number	XX.9				
∘ Ki-67 27%	Her 2 ISH Dual Probe Ratio	XX.9				
Disregard specimens from small tumor!	Ki-67	27.0				

